Featured Studies Results
Keyword: BRCA1
ADHERE: Survey about Pancreatic Cancer Screening Options for People with Inherited Risk
https://www.facingourrisk.org/research-clinical-trials/study/368/adhere-survey-about-pancreatic-cancer-screening-options-for-people-with-inherited-risk
Surveys, Registries, Interviews
Online survey about pancreatic cancer screening for people with an inherited mutation in genes that are linked to an increased risk of pancreatic cancer
NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/314/neptune-using-parp-inhibitors-before-surgery-in-localized-prostate-cancer
Clinicaltrials.gov identifier:
NCT05498272 (https://clinicaltrials.gov/show/NCT05498272)
Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations
Vaccine for People at High Risk for Pancreatic Cancer
https://www.facingourrisk.org/research-clinical-trials/study/365/vaccine-for-those-at-high-risk-of-developing-pancreatic-cancer
Clinicaltrials.gov identifier:
NCT05013216 (https://clinicaltrials.gov/show/NCT05013216)
Prevention
Phase 1 pancreatic cancer prevention study for people at high risk
Research Study on the Genetics of Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/317/research-study-on-the-genetics-of-breast-cancer
Clinicaltrials.gov identifier:
NCT06773897 (https://clinicaltrials.gov/show/NCT06773897)
Surveys, Registries, Interviews
A registry for anyone aged 18 and older who lives in the United States
Using a Shorter Type of MRI as a Screening Tool for People at High Risk for Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/353/using-biparametric-magnetic-resonance-imaging-mri-as-a-screening-tool-for-those-at-high-risk-for-prostate-cancer
Clinicaltrials.gov identifier:
NCT05384535 (https://clinicaltrials.gov/show/NCT05384535)
Prevention
Screening for people at high risk for prostate cancer
Treating Advanced Cancers with BRCA or Other Related Gene Mutations Using Targeted Therapy MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib
https://www.facingourrisk.org/research-clinical-trials/study/328/treating-advanced-cancers-with-dna-repair-mutations-using-moma-313-alone-or-in-combination-with-the-parp-inhibitor-olaparib
Clinicaltrials.gov identifier:
NCT06545942 (https://clinicaltrials.gov/show/NCT06545942)
Treatment
Treatment study for people with advanced or metastatic cancers
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/300/study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors
Clinicaltrials.gov identifier:
NCT05932862 (https://clinicaltrials.gov/show/NCT05932862)
Treatment
Treatment study for people with advanced solid tumors
Using a PARP Inhibitor and Oral Chemotherapy to Treat Advanced Solid Tumors with a Mutation in BRCA1, BRCA2, PALB2, ATM or CHEK2
https://www.facingourrisk.org/research-clinical-trials/study/376/using-a-parp-inhibitor-and-oral-chemotherapy-to-treat-advanced-solid-tumors-with-a-mutation-in-brca1-brca2-palb2-atm-or-chek2
Clinicaltrials.gov identifier:
NCT06177171 (https://clinicaltrials.gov/show/NCT06177171)
Treatment
Phase 1 treatment study for metastatic solid tumors
Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer in People with a BRCA Mutation or a Biomarker Called HRD
https://www.facingourrisk.org/research-clinical-trials/study/361/testing-olaparib-for-one-or-two-years-with-or-without-bevacizumab-to-treat-ovarian-cancer-with-a-brca-mutation-or-a-biomarker-called-hrd
Clinicaltrials.gov identifier:
NCT06580314 (https://clinicaltrials.gov/show/NCT06580314)
Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD
A Study of the PARP Inhibitor Saruparib Added to Standard Treatment for High Risk BRCA-Positive Prostate Cancer (EvoPAR PR02)
https://www.facingourrisk.org/research-clinical-trials/study/369/a-study-of-the-parp-inhibitor-saruparib-added-to-standard-treatment-for-high-risk-brca1-positive-prostate-cancer
Clinicaltrials.gov identifier:
NCT06952803 (https://clinicaltrials.gov/show/NCT06952803)
Treatment
Phase 3 treatment study for BRCA-positive high-risk prostate cancer
A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with an ATM, BRCA1/2, CHEK2, PALB2 or Other Mutation
https://www.facingourrisk.org/research-clinical-trials/study/377/an-new-targeted-therapy-cx5461-to-treat-advanced-breast-ovarian-pancreatic-or-prostate-cancer-with-inherited-or-tumor-mutations
Clinicaltrials.gov identifier:
NCT04890613 (https://clinicaltrials.gov/show/NCT04890613)
Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer
Pancreatic Cancer Screening Study for People with ATM, BRCA1, BRCA2 or PALB2 Mutations
https://www.facingourrisk.org/research-clinical-trials/study/330/screening-study-for-pancreatic-cancer
Clinicaltrials.gov identifier:
NCT05058846 (https://clinicaltrials.gov/show/NCT05058846)
Prevention
Pancreatic cancer screening study for people with ATM, BRCA1, BRCA2 or PALB2 mutations
Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)
https://www.facingourrisk.org/research-clinical-trials/study/349/studying-a-new-parp-inhibitor-and-hormonal-therapy-to-treat-her2-negative-hr-positive-metastatic-breast-cancer-with-a-brca1-brca2-or-palb2-mutation-evopar-br01
Clinicaltrials.gov identifier:
NCT06380751 (https://clinicaltrials.gov/show/NCT06380751)
Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation
A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)
https://www.facingourrisk.org/research-clinical-trials/study/101/a-study-to-compare-two-surgical-procedures-in-women-with-brca1-mutations-to-assess-reduced-risk-of-ovarian-cancer-sorock
Clinicaltrials.gov identifier:
NCT04251052 (https://clinicaltrials.gov/show/NCT04251052)
Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries
Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug, Axatilimab, Combined with Olaparib
https://www.facingourrisk.org/research-clinical-trials/study/345/treating-her2-negative-brca12-or-palb2-positive-metastatic-breast-cancer-using-a-new-drug-combined-with-olaparib
Clinicaltrials.gov identifier:
NCT06488378 (https://clinicaltrials.gov/show/NCT06488378)
Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation
Pancreatic Cancer Screening Study (CAPS5)
https://www.facingourrisk.org/research-clinical-trials/study/222/pancreatic-cancer-screening-studycaps5
Clinicaltrials.gov identifier:
NCT02000089 (https://clinicaltrials.gov/show/NCT02000089)
Prevention
Screening study for people at high risk for pancreatic cancer
Registry for People at Increased Risk for Pancreatic Cancer
https://www.facingourrisk.org/research-clinical-trials/study/331/registry-for-people-at-increased-risk-for-pancreatic-cancer
Clinicaltrials.gov identifier:
NCT06151223 (https://clinicaltrials.gov/show/NCT06151223)
Surveys, Registries, Interviews
Study collecting blood samples and imaging records of people at high risk of developing pancreatic cancer
Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/304/olaparib-with-cediranib-or-ceralasertib-for-people-with-advanced-or-metastatic-breast-cancer-and-with-a-brca1-or-brca2-mutation
Clinicaltrials.gov identifier:
NCT04090567 (https://clinicaltrials.gov/show/NCT04090567)
Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.